Li H.,Shanghai JiaoTong University |
Luo J.,Fudan University |
Wang C.,Beijing Anding Hospital |
Xie S.,Nanjing Brain Hospital |
And 5 more authors.
Schizophrenia Research | Year: 2014
Objective: Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia. The efficacy as well as safety of aripiprazole in Western populations has been described. The objective of this study is to investigate the efficacy, safety, and tolerability of aripiprazole and risperidone in Chinese Han schizophrenia subjects in mainland China. Method: The 6-week, double-blind, randomized, parallel study was conducted in 5 medical centers in mainland China from November 2007 to March 2011. A total of 279 subjects with a primary DSM-IV diagnosis of schizophrenia were randomly assigned (with a randomization ratio of 1:1) to aripiprazole (n. = 139) or risperidone (n. = 140). Efficacy measurements included the Positive and Negative Syndrome Scale (PANSS) total, positive, negative and general psychopathology subscale scores, and Clinical Global Impressions-Severity of Illness (CGI-S), and Improvement scale scores. Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were also assessed as measures of safety and tolerability. Results: Both the aripiprazole and risperidone groups showed statistically significant improvement of PANSS total, positive, negative, general psychopathology subscale scores, and CGI-S scores from baseline to the endpoint (all p<. 0.01). Significant improvement was noted in the first week for both treatment groups. There were no significant differences in efficacy measurements between the two treatment groups. Mean change of PANSS total scores from baseline to the endpoint was - 26.8. ±. 18.1 for aripiprazole and - 30.0. ±. 17.7 for risperidone, (p= 0.1475). The responder rate was 71% (n. = 99) and 76% (n. = 107) for aripiprazole and risperidone, respectively, (p= 0.323). The incidences of EPS were similar in the aripiprazole (25%, n. = 35) and risperidone groups (24%, n. = 34), respectively (p= 0.757). No clinically meaningful effects on QTc interval, QRS duration, or PR interval were observed in either treatment groups. However, the incidence of clinically significant weight gain (p= 0.0118) and hyperprolactinemia (p<. 0.001) in the aripiprazole group was significantly lower than in the risperidone group. Conclusion: The study demonstrated that aripiprazole, as well as risperidone, had rapid and persistent efficacy for psychotic symptoms from the first week of therapy. There may be poor efficacy for aripiprazole compared with risperidone for overall improvement, but there were no significant differences in this study. Aripiprazole showed good tolerability with less weight gain and hyperprolactinemia compared with risperidone. The overall efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects were similar to that reported in Western populations. © 2014.
PubMed | Shanghai JiaoTong University, Shandong University, Suzhou University, University of Sichuan and 4 more.
Type: | Journal: Drug design, development and therapy | Year: 2017
Pramipexole (PPX), a non-ergot dopamine receptor agonist, is a first-line treatment for Parkinsons disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been examined.Chinese PD patients (n=464) were retrospectively analyzed by PPX maintenance dose, PD stage, combined levodopa dose, and baseline tremor contribution. The sum score of Baseline Activities of Daily Living (part II) and Motor Examination (III) of the Unified Parkinsons Disease Rating Scale (UPDRS II+III) was used as a covariate for final score adjustment.Sustained-release (SR) and immediate-release (IR) PPX showed similar efficacy based on score changes at 18 weeks, with comparable tolerability. Approximately two-third of patients received PPX at 1.5 mg/d, and one fourth of patients had 20% tremor contribution to UPDRS II+III. After treatment, patients receiving PPX 1.5 mg/d showed better improvement in UPDRS II+III scores (UPDRS II+III improvement was better with PPX 1.5 than with <1.5 mg/d in Chinese PD patients after 18 weeks of treatment, with similar trends seen with IR and SR formulations. The frequency of AEs in PPX 1.5 and <1.5 mg/d subgroups was similar.
Chen Y.,Centers for Disease Control and Prevention |
Ma F.,Centers for Disease Control and Prevention |
Zhang J.,Centers for Disease Control and Prevention |
Chu X.,Peoples Hospital of Jiangsu Province |
Xu Y.,Nanjing Brain Hospital
European Journal of Neurology | Year: 2014
Background and purpose: It is important to have an estimate of the incidence of Guillain-Barré syndrome (GBS) because of the expansion of vaccination programs and the associated risks of vaccine-related GBS. Incidence information in Asia, especially in China, is scarce. This study attempts to describe GBS incidence in large Chinese populations located in three geographically different and moderately distant areas of the same province. Methods: The surveyed areas were Nanjing, Yancheng and Xuzhou, which are three cities in Jiangsu province in China. Nanjing is in the south of Jiangsu province, Yancheng is in the middle and Xuzhou is in the north. The survey was carried out in regions that might have received patients meeting the case definition from 2008 to 2010. The population numbers came from the local Bureau of Statistics. Data analysis was conducted in 2011. Results: The incidence of GBS was 0.59 cases per 100 000 person-years. The GBS incidence increased with age amongst people <80 years old. Males had a higher incidence of GBS than females. GBS incidence in Nanjing was the highest amongst the three regions. Conclusions: The incidence rates in parts of Jiangsu province were lower than those in Europe and North America. There was one peak in incidence amongst older adults (70-80 years). Geographical differences in GBS incidence rates may be related to socioeconomic status. There were no significant seasonal variations of incidence in Jiangsu. © 2013 EFNS.
Zhang X.R.,Nanjing Southeast University |
Zhang X.R.,Queen's University of Belfast |
Zhang Z.J.,Nanjing Southeast University |
Zhu R.X.,Nanjing Brain Hospital |
And 4 more authors.
Pharmacogenomics | Year: 2011
Aim: Sexual dysfunction induced by antipsychotic drug treatment is under investigated and under reported. This study aimed to determine the influence of genetic polymorphisms in the D2 dopamine receptor (DRD2) and endothelial nitric oxide synthase (eNOS) genes, and the possible role of blood prolactin concentrations on sexual function in schizophrenic patients. Materials & methods: Male remitted schizophrenic patients (n = 100), who were living with a sexual partner and receiving antipsychotic drug monotherapy for at least 6 months, were assessed for sexual and erectile dysfunction using the Arizona Sexual Experience Scale and the five-item version of the International Index of Erectile Function. Blood samples were taken for plasma prolactin determination and genotyped for four polymorphisms: DRD2 (-141C Ins/Del and Taq1A) and eNOS gene (G894T and T-786C). Results: The-141C Ins/Del, but not Taq1A, polymorphism of the DRD2 gene was significantly associated with sexual dysfunction with the del allele being less frequent in sexual dysfunction subjects. Neither of the eNOS polymorphisms, G894T or T-786C, was significantly associated with sexual or erectile dysfunction. Prolactin concentrations were significantly higher in patients with erectile dysfunction but did not reach significance in those with sexual dysfunction. Prolactin was also reduced in-141C Del allele carriers. The frequency and severity of sexual dysfunction in the patients receiving typical antipsychotics was significantly greater than those receiving risperidone or clozapine, while prolactin concentrations were significantly higher in subjects receiving risperidone compared with those receiving clozapine or typical antipsychotics. Conclusion: This is the first evidence indicating that antipsychotic drug treatment in men is associated with a variant in the DRD2 gene in which the-141C Del allele might be a protective factor. While this may, in part, be mediated by effects on prolactin, other factors are likely to contribute to the greater sexual dysfunction in patients receiving typical antipsychotics. © 2011 Future Medicine Ltd.
Zhu X.,Nanjing Southeast University |
Dong J.,Nanjing Brain Hospital |
Shen K.,Nanjing Southeast University |
Bai Y.,Nanjing Southeast University |
And 4 more authors.
Brain Research Bulletin | Year: 2015
The N-methyl- d-aspartate (NMDA) receptor plays an important role in the pathophysiology of several neurological diseases, including epilepsy. The present study investigated the effect of NMDA receptor NR2B subunits on pentylenetetrazole (PTZ)-kindling-induced pathological and biochemical events in mice. Our results showed that PTZ-kindling up-regulates the expression of NMDA receptor NR2B subunits in the hippocampus and that kindled mice were characterized by significant astrocytosis and neuron loss in the hippocampus. Oxidative stress, including excessive malondialdehyde (MDA) production and decreased enzymatic activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX), were detected in the hippocampus after the mice were fully kindled. Additionally, expression of brain-derived neurotrophic factor (BDNF) in the hippocampus was found to be up-regulated in PTZ-kindled mice. However, selectively blocking NMDA receptor NR2B subunits by ifenprodil significantly suppressed PTZ-kindling-induced hippocampal astrocytosis, oxidative stress and neuron loss. Furthermore, blocking NMDA receptor NR2B subunits also abolished PTZ-kindling-induced BDNF expression. These results indicate that NMDA receptor NR2B subunits contribute to epilepsy-associated pathological and biochemical events, including hippocampal astrocytosis, oxidative stress and neuron loss, and these events might be correlated with up-regulation of BDNF expression. © 2015 Elsevier Inc.
Zhang X.R.,Nanjing Southeast University |
Zhang X.R.,Queen's University of Belfast |
Zhang Z.J.,Nanjing Southeast University |
Jenkins T.A.,Queen's University of Belfast |
And 2 more authors.
Journal of Sexual Medicine | Year: 2011
Introduction. Antipsychotic drug-induced sexual dysfunction is a common and problematic side effect, which may diminish quality of life and lead to treatment noncompliance. Up to date, there is still a scarcity of basic research regarding the chronic effects of most antipsychotic agents on sexual behavior. Aim. The present study investigated the effect of a range of doses of three antipsychotic drugs (haloperidol, risperidone, and quetiapine) on male rat sexual competence following chronic administration. Methods. Twelve groups of Sprague-Dawley rats (n=7 each) received by gavage haloperidol (0.25, 0.5, or 1mg/kg), risperidone (0.125, 0.25, or 0.5mg/kg), quetiapine (10, 20, and 40mg/kg) or vehicle (distilled water) in the corresponding control groups, respectively, once daily for 21 days. Sexual function was evaluated by the copulatory behavior test 10 hours after the last dose. Main Outcome Measure. The male rat behavioral parameters of copulatory test. Results. Sexual function was widely and significantly suppressed by high dose haloperidol (1mg/kg) after 21 days administration compared with the control group, which included both frequency and latency of intromission and ejaculation. Only ejaculation latency was significantly impaired after administration with 0.5mg/kg haloperidol. Compared with the control group, high dose risperidone (0.5mg/kg) significantly decreased the frequency of mounting. There were no significant changes in sexual behavior with the lower doses of either haloperidol or risperidone. Sexual behavior was not influenced by any dose of quetiapine. Conclusions. Haloperidol and risperidone, but not quetiapine, could impair sexual competence in a dose-related manner in male rats. © 2010 International Society for Sexual Medicine.
Wang W.,Nanjing Medical University |
Li Q.,Nanjing Medical University |
Pan Y.,Nanjing Medical University |
Zhu D.,Nanjing Brain Hospital |
Wang L.,Nanjing Medical University
Respirology | Year: 2013
Background and objective: Sleep disorders are a complicated and major public health concern affecting millions of individuals. Obstructive sleep apnoea (OSA) is a common but still under-recognized disease which can cause intermittent nocturnal hypercapnia. Neuropeptides play critical roles in neurotransmission, acting as transmitters or modulators. Results from recent studies have implicated several neuropeptides in sleep and breathing regulation, including orexin, neuropeptides Y and galanin. Therefore, the present study aimed to evaluate the influence of hypercapnia on these neuropeptides and their receptors in order to assess their potential role in the pathogenesis of OSA. Methods: Fifteen C57BL/6J mice were randomly divided into three groups and exposed to moderate hypercapnia (5% CO2 with balanced room air), or severe hypercapnia (10% CO2 with balanced room air) or room air for 3 h (9:00-12:00 h), respectively. Immediately following exposure the brainstem and hypothalamus were excised for real-time reverse transcription polymerase chain reaction and western blot analyses. Results: In the hypothalamus gene expression including galanin, orexin and neuropeptide Y receptor 1 (NPYR1) was downregulated by hypercapnia. However, protein and mRNA levels of orexin-A receptor were upregulated by severe hypercapnia. In the brainstem only NPYR1 mRNA expression was decreased in moderate hypercapnia compared with that in severe hypercapnia. Conclusions: These findings suggest that hypercapnia can affect these neuropeptides and their receptors, especially the orexin and orexin-A receptor. The potential relationships between these peptides and OSA are worthy of further investigation. © 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology.
Wang X.,Nanjing Medical University |
Zhang J.,Nanjing Brain Hospital |
Liu Y.,Nanjing Medical University |
Zhang Y.,Nanjing Brain Hospital
Journal of Biomedical Research | Year: 2011
The aim of present study was to investigate the relationship between nerve injury-induced protein 2 (NINJ2) gene polymorphism and stroke in Chinese Han population. Fifty-two patients with large-artery atherosclerosis (LAA) infarction, 85 patients with small-artery occlusion lacunar (SAO) infarction, 50 patients with intracerebral hemorrhage (ICH) and 66 controls were included. Genotypes and alleles frequencies of the two single nucleotide polymorphisms (SNPs) of NINJ2 among different groups were analyzed and compared. In regard to rs12425791, the frequencies of the AG and AA+. AG genotypes of the LAA and SAO groups were significantly higher than those in the control group; the frequency of the A allele of the SAO group was significantly higher than that of the control group. In regard to rs11833579, there were not any significant differences between the case and the control groups. The SNP rs12425791 is significantly associated with ischemic stroke, and the A allele increases the susceptibility to stroke. The SNP rs11833579 is not significantly associated with stroke. © 2011 The Editorial Board of Journal of Biomedical Research.
Liu H.,Nanjing Medical University |
Ge H.,Nanjing Medical University |
Xiang J.,Cincinnati Childrens Hospital Medical Center |
Miao A.,Nanjing Medical University |
And 5 more authors.
Journal of Headache and Pain | Year: 2015
Background: Recent advances in migraine research have shown that the cerebral cortex serves a primary role in the pathogenesis of migraine. Since aberrant brain activity in migraine can be noninvasively detected with magnetoencephalography (MEG), The object of this study was to investigate the resting state cortical activity differences between migraineurs and controls and its related clinical characteristics. Methods: Twenty-two subjects with an acute migraine and twenty-two age- and gender-matched controls were studied using MEG. MEG recordings were recorded 120 seconds during the headache attack. Analyze MEG signals from low (1–4 Hz) to high (200–1000 Hz)-frequency ranges. Results: In comparison with the controls, brain activity in migraine subjects was significantly different from that of the controls both in two frequency ranges (55–90 Hz, p < 0.001) and (90–200 Hz, p < 0.004). But the power value showed no significantly differences between control and migraines in all frequency ranges (p > 0.05). All the clinical characteristics had no significant correlation with aberrant brain activity. Conclusions: The results demonstrated that migraine subjects in resting state had significantly aberrant ictal brain activity that can be measured with neuromagnetic imaging techniques. The findings may facilitate the development of new therapeutic strategies in migraine treatment via alterations in cortical excitability with TMS and other medications in the future. © 2015, Liu et al.; licensee Springer.
Liu N.,Central South University |
Liu N.,Nanjing Brain Hospital |
Zhang Y.,Central South University |
Brady H.J.,Yale University |
And 2 more authors.
Aggressive Behavior | Year: 2012
This study investigates the role of borderline personality disorder (BPD) and antisocial personality disorder (ASPD) features as mediators of the effects of childhood maltreatment on severe intrafamilial physical violence amongst Chinese male perpetrators. A cross-sectional survey and face-to-face interview were conducted to examine childhood maltreatment, personality disorder features, impulsivity, aggression, and severe intrafamilial physical violence in a community sample of 206 abusive men in China. The results suggest that ASPD or BPD features mediate between childhood maltreatment and intimate partner violence perpetration in Chinese abusive men. These findings may yield clinical and forensic implications for assessing the psychopathology of abusive men, and may steer the intervention of intimate partner violence. © 2011 Wiley Periodicals, Inc.